Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05758623
Other study ID # P_204970118082038
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2021
Est. completion date March 31, 2024

Study information

Verified date February 2023
Source Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd
Contact Ming Zhang, MD.
Phone +86 15817386880
Email zhangming1307@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The subjects of this study are patients with non-load-bearing bone defects of the extremities who need bone grafting surgery. The patients was treated with bone graft using magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd.. Three follow-up visits were performed at the 12th, 24th and 36th weeks after bone grafting, the clinical role for bone will be assessed.


Description:

The subjects of this study are patients with non-load-bearing bone defects of the extremities who need bone grafting surgery. The subjects were randomly divided into experimental group and control group. The experimental group was treated with bone graft using magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd., while the control group was treated with bone graft β- Tricalcium phosphate bioceramics were used for bone transplantation. Three follow-up visits were performed at the 12th, 24th and 36th weeks after bone grafting. It is estimated that 176 cases will be recruited in total, and 135 cases have been recruited since April 2021. This product can be degraded and absorbed in vivo, and it can promote the formation of new bone.


Recruitment information / eligibility

Status Recruiting
Enrollment 176
Est. completion date March 31, 2024
Est. primary completion date April 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age = 18 years old and = 75 years old, regardless of gender; 2. Bone defect exists in one of the following anatomical positions, and bone grafting is required: Upper limb bones: humerus, ulna, radius, metacarpus, carpus, phalanges; Lower limb bones: femur, tibia, fibula, calcaneus, navicular bone, wedge bone, cuboid bone, metatarsal bone, talus and phalanges; 3. The maximum diameter of the expected or actual three-dimensional bone defect is = 0.5cm and = 6cm, and the defect is only one; 4. The bone defect site is expected to be fixed with non-degradable internal fixation system during operation; 5. Subjects or their legal representatives can understand the purpose of the study and show sufficient compliance with the study protocol and sign the informed consent form. Exclusion Criteria: 1. The blood glucose control is unstable and cannot meet the operation conditions; 2. Severe coagulation dysfunction (PT or APTT = 2 times the upper limit of normal value); 3. History of arterial thrombosis attack (such as stroke, angina pectoris, acute myocardial infarction, etc.) or NYHA grade = III within 3 months before enrollment; 4. Oral or injection of sedative and hypnotic drugs or non-steroidal anti-inflammatory drugs (except aspirin) every week within 3 months before enrollment; 5. He had received chemotherapy drugs or radiotherapy within 3 months before admission; 6. Cumulative oral or injection of corticosteroids or various growth factors for = 14 days within 1 month before enrollment; 7. Suffering from systemic infection or uncontrollable local infection, serious soft tissue injury at the proposed operation site, serious vascular or nerve injury, malignant tumor, confirmed severe malnutrition or other important organ failure; 8. The limb to be operated on has osteofascial compartment syndrome; 9. Structural bone grafting is required; 10. Pregnant or lactating women; 11. Participate in clinical trials of other drugs or medical devices within one month before enrollment; 12. For the benefit of the subject, the researcher believes that it should not participate in other situations of this clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Device
The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. Control group application ß- Tricalcium phosphate bioceramics for treatment.

Locations

Country Name City State
China Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd Shenzhen Guangdong

Sponsors (3)

Lead Sponsor Collaborator
Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd Chinese University of Hong Kong, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bone graft fusion rate When Mg-containing degradable polymer bone repair material is used to repair non-load-bearing bone defects of limbs, the main effective evaluation index is bone graft fusion rate at 24 weeks after operation 24 weeks after standard operation
Secondary to evaluate the bone graft fusion rate to evaluate the bone graft fusion rate at 12 and 36 weeks after operation 12 and 36 weeks after operation
Secondary Improvement level of SF-36 scale and satisfaction of device operation Improvement level of SF-36 scale and satisfaction of instrument operation at 36 weeks after operation at 36 weeks after operation
See also
  Status Clinical Trial Phase
Completed NCT03076138 - Gene-activated Bone Substitute for Maxillofacial Bone Regeneration N/A
Recruiting NCT03570606 - Clinical Study of Bone Graft Substitutes in Orthopaedic and Spinal Applications.
Completed NCT01738113 - Open Versus Closed Kinetic Chain Exercises in Tibial Distraction Osteogenesis by Ilizarov's METHOD Phase 2
Active, not recruiting NCT06312384 - The Influence of 3D Surgical Template on the Contour of Bone Augmentation, in Patient With Labial Alveolar Ridge Defect and Simultaneous Implantation Phase 3
Not yet recruiting NCT05676905 - Prospective Multicenter Observational Study on the Use of NEOCEMENT® for the Treatment of Bone Defects
Active, not recruiting NCT05659069 - Influence of Mandibular Nerve Lateralization on Nutrition and Speech